179 related articles for article (PubMed ID: 27466381)
1. Cadherin 5 expression correlates with poor survival in human gastric cancer.
Higuchi K; Inokuchi M; Takagi Y; Ishikawa T; Otsuki S; Uetake H; Kojima K; Kawano T
J Clin Pathol; 2017 Mar; 70(3):217-221. PubMed ID: 27466381
[TBL] [Abstract][Full Text] [Related]
2. Cadherin 5 Is a Significant Risk Factor for Hematogenous Recurrence and a Prognostic Factor in Locally Advanced Gastric Cancer.
Inokuchi M; Higuchi K; Takagi Y; Tanioka T; Nakagawa M; Gokita K; Okuno K; Kojima K
Anticancer Res; 2017 Dec; 37(12):6807-6813. PubMed ID: 29187459
[TBL] [Abstract][Full Text] [Related]
3. Relationship between expression of IGFBP7 and clinicopathological variables in gastric cancer.
Sato Y; Inokuchi M; Takagi Y; Otsuki S; Fujimori Y; Yanaka Y; Kobayashi K; Higuchi K; Kojima K; Kawano T
J Clin Pathol; 2015 Oct; 68(10):795-801. PubMed ID: 26043748
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of PAK4 expression in gastric cancer.
Kobayashi K; Inokuchi M; Takagi Y; Otsuki S; Fujimori Y; Sato Y; Yanaka Y; Higuchi K; Aburatani T; Tomii C; Uetake H; Kojima K; Kawano T
J Clin Pathol; 2016 Jul; 69(7):580-5. PubMed ID: 26614788
[TBL] [Abstract][Full Text] [Related]
5. Expression of moesin and CD44 is associated with poor prognosis in gastric adenocarcinoma.
Jung WY; Kang Y; Lee H; Mok YJ; Kim HK; Kim A; Kim BH
Histopathology; 2013 Oct; 63(4):474-81. PubMed ID: 23889297
[TBL] [Abstract][Full Text] [Related]
6. Expression of ribophorine II is a promising prognostic factor in human gastric adenocarcinoma.
Fujimoto D; Goi T; Hirono Y
Int J Oncol; 2017 Feb; 50(2):448-456. PubMed ID: 28035352
[TBL] [Abstract][Full Text] [Related]
7. Prognostic importance of RASSF2 expression in patients with gastric cancer who had undergone radical gastrectomy.
Aydin D; Bilici A; Kayahan S; Yavuzer D; Basar M; Aliustaoglu M
Clin Transl Oncol; 2016 Jun; 18(6):608-16. PubMed ID: 26459248
[TBL] [Abstract][Full Text] [Related]
8. TEM1 expression in cancer-associated fibroblasts is correlated with a poor prognosis in patients with gastric cancer.
Fujii S; Fujihara A; Natori K; Abe A; Kuboki Y; Higuchi Y; Aizawa M; Kuwata T; Kinoshita T; Yasui W; Ochiai A
Cancer Med; 2015 Nov; 4(11):1667-78. PubMed ID: 26336878
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of Ras-GTPase-activating protein SH3 domain-binding protein 1 correlates with poor prognosis in gastric cancer patients.
Min L; Ruan Y; Shen Z; Jia D; Wang X; Zhao J; Sun Y; Gu J
Histopathology; 2015 Nov; 67(5):677-88. PubMed ID: 25809930
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of N-cadherin expression in gastric cancer.
Kamikihara T; Ishigami S; Arigami T; Matsumoto M; Okumura H; Uchikado Y; Kita Y; Kurahara H; Kijima Y; Ueno S; Natsugoe S
Pathol Int; 2012 Mar; 62(3):161-6. PubMed ID: 22360503
[TBL] [Abstract][Full Text] [Related]
11. Vimentin expression is associated with decreased survival in gastric cancer.
Otsuki S; Inokuchi M; Enjoji M; Ishikawa T; Takagi Y; Kato K; Yamada H; Kojima K; Sugihara K
Oncol Rep; 2011 May; 25(5):1235-42. PubMed ID: 21327330
[TBL] [Abstract][Full Text] [Related]
12. Adenocarcinoma in the middle third of the stomach--an evaluation for the prognostic significance of clinicopathological features.
Sheen-Chen SM; Chou CW; Chen MC; Chen FC; Chen YS; Chen JJ
Hepatogastroenterology; 1997; 44(17):1488-94. PubMed ID: 9356878
[TBL] [Abstract][Full Text] [Related]
13. Low CA II expression is associated with tumor aggressiveness and poor prognosis in gastric cancer patients.
Hu X; Huang Z; Liao Z; He C; Fang X
Int J Clin Exp Pathol; 2014; 7(10):6716-24. PubMed ID: 25400751
[TBL] [Abstract][Full Text] [Related]
14. Analysis of a cytoskeleton-associated kinase PEAK1 and E-cadherin in gastric cancer.
Guo Q; Qin W; Li B; Yang H; Guan J; Liu Z; Li S
Pathol Res Pract; 2014 Dec; 210(12):793-8. PubMed ID: 25445115
[TBL] [Abstract][Full Text] [Related]
15. Expression of pyruvate dehydrogenase is an independent prognostic marker in gastric cancer.
Sun XR; Sun Z; Zhu Z; Guan HX; Li CY; Zhang JY; Zhang YN; Zhou H; Zhang HJ; Xu HM; Sun MJ
World J Gastroenterol; 2015 May; 21(17):5336-44. PubMed ID: 25954108
[TBL] [Abstract][Full Text] [Related]
16. High expression of HER3 is associated with a decreased survival in gastric cancer.
Hayashi M; Inokuchi M; Takagi Y; Yamada H; Kojima K; Kumagai J; Kawano T; Sugihara K
Clin Cancer Res; 2008 Dec; 14(23):7843-9. PubMed ID: 19047113
[TBL] [Abstract][Full Text] [Related]
17. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
18. Correlation of decreased expression of PHLDA1 protein with malignant phenotype of gastric adenocarcinoma.
Zhao P; Lu Y; Liu L
Int J Clin Exp Pathol; 2015; 8(5):5230-5. PubMed ID: 26191222
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer.
Alakus H; Grass G; Hennecken JK; Bollschweiler E; Schulte C; Drebber U; Baldus SE; Metzger R; Hölscher AH; Mönig SP
Histol Histopathol; 2008 Aug; 23(8):917-23. PubMed ID: 18498066
[TBL] [Abstract][Full Text] [Related]
20. Efficient isolation and proteomic analysis of cell plasma membrane proteins in gastric cancer reveal a novel differentiation and progression related cell surface marker, R-cadherin.
Chen B; Luo QC; Chen JB; Lin LE; Luo MX; Ren HY; Chen PQ; Shi LG
Tumour Biol; 2016 Sep; 37(9):11775-11787. PubMed ID: 27029387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
